• Loading (Have a toke while you wait)...

Emerald Health Therapeutics, Inc.(“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced that its Québec facility, Verdélite, has received its Standard Processing License from Health Canada. This license means that, in addition to Verdélite’s right to cultivate and sell cannabis flowers, it can now extract, manufacture, synthesize, test and sell next-generation cannabis products and will position Verdélite to launch these products in conjunction with the expected legalization of a broader spectrum of cannabis products in Canada in October 2019. The license also allows Verdélite to build and operate a laboratory for research and development of cannabis-based products.

“The ability to carry out research and development on cannabis, and to extract cannabinoids and manufacture next-generation cannabis products are important steps forward for Verdélite,” said Thierry Schmidt, President of Verdélite. “This processing license will allow us to develop and offer a wide-range of high-quality cannabis products, advance Verdélite and Emerald brands, and to serve recreational and medicinal consumers in Quebec and throughout Canada.”

This is the third processing license issued to Emerald by Health Canada.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is licensed to cultivate in 1.03 million square feet of the first of its two 1.1 million square foot greenhouses. The capacity of each greenhouse is estimated to exceed 75,000 kg of cannabis annually. The initial greenhouse has been scaling up production over the last four quarters and is expected to be fully planted in April. Emerald’s Verdélite operation in Québec is completing the build out of its 88,000 square foot indoor cultivation facility and is scaling up production. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.

Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products aimed at providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Investor Relations 
(800) 757 3536 Ext. #5

VANCOUVER, British Columbia, April 08, 2019 (GLOBE NEWSWIRE)

Please visit www.emeraldhealth.ca for more information

Leave a Reply

Your email address will not be published. Required fields are marked *